Nebulized Recombinant Tissue Plasminogen Activator (rt-PA) for Acute COVID-19-Induced Respiratory Failure: An Exploratory Proof-of-Concept Trial
Authors:
- Pratima ChowdaryPCPratima Chowdary
- Banwari AgarwalBABanwari Agarwal
- Maria Rita PeraltaMPMaria Rita Peralta
- Sanjay BhaganiSBSanjay Bhagani
- Simon LeeSLSimon Lee
- James GoldringJGJames Goldring
- Marc LipmanMLMarc Lipman
- Emal WaqifEWEmal Waqif
- Mark PhillipsMPMark Phillips
- Helen PhilippouHPHelen Philippou
- Jonathan H. FoleyJFJonathan H. Foley
- Nicola J. MutchNMNicola J. Mutch
Open Access
- 8 September 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5848
Abstract
Acute lung injury in COVID-19 results in diffuse alveolar damage with disruption of the alveolar-capillary barrier, coagulation activation, alveolar fibrin deposition and pulmonary capillary thrombi. Nebulized recombinant tissue plasminogen activator (rt-PA) has the potential to facilitate localized thrombolysis in the alveolar compartment and improve oxygenation. In this proof-of-concept safety study, adults with COVID-19-induced respiratory failure and a 2/FiO2 (P/F) ratio requiring invasive mechanical ventilation (IMV) or non-invasive respiratory support (NIRS) received nebulized rt-PA in two cohorts (C1 and C2), alongside standard of care, between 23 April–30 July 2020 and 21 January–19 February 2021, respectively. Matched historical controls (MHC; n = 18) were used in C1 to explore efficacy. Safety co-primary endpoints were treatment-related bleeds and <1.0–1.5 g/L fibrinogen reduction. A variable dosing strategy with clinical efficacy endpoint and minimal safety concerns was determined in C1 for use in C2; patients were stratified by ventilation type to receive 40–60 mg rt-PA daily for ≤14 days. Nine patients in C1 (IMV, 6/9; NIRS, 3/9) and 26 in C2 (IMV, 12/26; NIRS, 14/26) received nebulized rt-PA for a mean (SD) of 6.7 (4.6) and 9.1(4.6) days, respectively. Four bleeds (one severe, three mild) in three patients were considered treatment related. There were no significant fibrinogen reductions. Greater improvements in mean P/F ratio from baseline to study end were observed in C1 compared with MHC (C1; 154 to 299 vs. MHC; 154 to 212). In C2, there was no difference in the baseline P/F ratio of NIRS and IMV patients. However, a larger improvement in the P/F ratio occurred in NIRS patients (NIRS; 126 to 240 vs. IMV; 120 to 188) and fewer treatment days were required (NIRS; 7.86 vs. IMV; 10.5). Nebulized rt-PA appears to be well-tolerated, with a trend towards improved oxygenation, particularly in the NIRS group. Randomized clinical trials are required to demonstrate the clinical effect significance and magnitude.Keywords
All Related Versions
Funding Information
- Royal Free Charity (Trust Fund 35)
- Boehringer Ingelheim (Trust Fund 35)
This publication has 35 references indexed in Scilit:
- Nebulized Fibrinolytic Agents Improve Pulmonary Fibrinolysis but Not Inflammation in Rat Models of Direct and Indirect Acute Lung InjuryPLOS ONE, 2013
- Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in micePulmonary Pharmacology & Therapeutics, 2010
- Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary DeliveryPharmaceutical Research, 2005
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003
- Coagulation, fibrinolysis, and fibrin deposition in acute lung injuryCritical Care Medicine, 2003
- The pulmonary physician in critical care * 6: The pathogenesis of ALI/ARDSThorax, 2002
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- The science of nebulised drug deliveryThorax, 1997
- Fibrinolytic activity in bronchoalveolar lavage of baboons with diffuse alveolar damageCritical Care Medicine, 1992